Rho激酶抑制剂对OX40及其配体mRNA在实验性变态反应性神经炎中表达的影响  

Expression of OX40/OX40L mRNA in experimental allergic neuritis under influence of Rho-kinase inhibitor

作　　者：张宁[1] 李刚[1] 肖波[1] 刘运海[1] 蔡艳[1] 孙新刚[1] 梁静慧[1] 

机构地区：[1]中南大学湘雅医院神经内科,长沙410008

出　　处：《中华神经科杂志》2010年第1期26-30,共5页Chinese Journal of Neurology

摘　　要：目的研究Rho激酶（ROK）抑制剂对OX40及其配体（OX40L）mRNA在实验性变态反应性神经炎（experimental allegic neuritis，EAN）大鼠坐骨神经、脾脏、外周血和淋巴结中表达的影响。方法54只Lewis大鼠随机分为EAN模型组、EAN＋ROK抑制剂干预组和完全弗氏佐剂对照（CFA）组。分别在免疫后第9、17、26天处死动物，取其坐骨神经根、脾脏、外周血单个核细胞和淋巴结，采用逆转录PCR（RT—PCR）技术检测OX40和OX40L mRNA在各组织的表达水平。结果EAN＋ROK抑制剂组大鼠OX40 mRNA在坐骨神经中第9、17、26天的表达分别为0．266±0．031、0．298±0．024和0．113±0．018；在淋巴结中第9、17、26天的表达分别为0．453±0．030、0．496±0．100和0．220＋0．016；OX40L mRNA在坐骨神经中第9、17、26天的表达分别为0．247±0．018、0．298±0．026和0．165±0．013；在淋巴结中第9、17、26天的表达分别为0．283±0．027、0．306±0．011和0．161±0．012。与EAN组比较，OX40和OX40L mRNA的表达明显降低（t=2．24～4．89，P〈0．05），坐骨神经炎性细胞浸润和脱髓鞘减轻。CFA组大鼠无症状。结论ROK抑制剂可以减轻EAN发病程度，抑制OX40／OX40L的表达可能是其作用机制之一。Objective To study the expression of mRNA of OX40 and OX40L in the sciatic nerve, spleen, peripheral blood mononuclear cells and lymph nodes of EAN under the influence of Rho-kinase inhibitor. Methods All 54 female Lewis rats were divided into 3 groups ： the EAN group, the EAN ± Rhokinase inhibitor group and the complete Freund＇ s adjuvant （CFA） group. The rats were sacrificed at 9, 17 and 26 days after immunized. Ox40 and OX40L mRNA were detected by RT-PCR which came from spleens, sciatic nerves, peripheral blood mononuckear cells and lymphonodes. Results In EAN ± Rho-kinase inhibitor group, the mRNA expression of OX40 were 0.266 ±0. 031, 0. 298 ±0. 024 and 0. 113 ±0. 018 at 9, 17 and 26 days in the sciatic nerve, the expression were 0. 453 ±0. 030, 0. 496 ± 0. 100 and 0. 220 ± 0. 016 in the lymph nodes. The mRNA expression of OX40L were 0. 247 ± 0. 018, 0. 298 ± 0. 026 and 0. 165 ±0. 013 in the sciatic nerve, the expression were 0. 283 ±0. 027, 0. 306 ±0. 011 and 0. 161 ±0. 012 in the lymph nodes. The mRNA expression of OX40 and OXdOL in EAN ± Rho-kinase inhibitor group was lower than EAN group at the three time points （ t = 2. 24-4. 89, P 〈 0.05 ）, and the demyelination and inflammation cells infiltrating were ameliorated in spinal nerve. CFA group didn＇ t show any clinical manifestation. Conclusion Rho-kinase inhibitor may ameliorate the development of EAN through inhabiting the OX40 and OX40L activation.

关 键 词：神经炎 自身免疫性 实验性 RHO相关激酶类 受体 OX40 OX40配体 

分 类 号：R285.5[医药卫生—中药学]